BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 36221356)

  • 21. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
    Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
    Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
    Lin J; Wang W; Lin J; Chen R; Cao Y
    J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
    Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (
    Li J; Huang K; Ji H; Qian J; Lu H; Zhang Y; Russo A; Romero A; Urbanska EM; Tabbò F; Zhao X; Chu T
    Transl Lung Cancer Res; 2023 Dec; 12(12):2505-2519. PubMed ID: 38205204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
    Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis.
    Cheng W; Qian C; Zhang H; Meng Q; Yin JC; Fang S
    Anticancer Drugs; 2022 Nov; 33(10):1182-1185. PubMed ID: 35946559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
    Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
    Yuan Y; Wang Z; Nie X; Zhang P; Li L
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
    de Figueiredo-Pontes LL; Wong DW; Tin VP; Chung LP; Yasuda H; Yamaguchi N; Nakayama S; Jänne PA; Wong MP; Kobayashi SS; Costa DB
    J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
    Dong W; Lei P; Liu X; Li Q; Cheng X
    Front Immunol; 2021; 12():686057. PubMed ID: 34804000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
    Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
    Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
    Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
    Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
    Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
    [No Abstract]   [Full Text] [Related]  

  • 40. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.